Pamela brings extensive experience providing CMC leadership and technical expertise across multiple complex subretinal gene therapy programmes. With nearly two decades of industry experience, she has held key CMC roles at organisations including Biogen, Nightstar Therapeutics and the Cell and Gene Therapy Catapult. Her background spans end-to-end development activities, with a strong track record in CDMO management, technical oversight, and guiding advanced therapy programmes through critical development and regulatory milestones and into clinical trials.